Generic Product News (September 2017)

SEPTEMBER 25, 2017


MESALAMINE DELAYED-RELEASE TABLETS
MARKETED BY:
Zydus Pharmaceuticals (USA) Inc
COMPARE TO: Lialda (Shire)
INDICATION: Zydus has launched Mesalamine Delayed-Release Tablets, 1.2 g, the first AB-rated equivalent to Lialda. The drug is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis, and for the maintenance of remission of ulcerative colitis.
DOSAGE FORM: Delayed-release tablet, 1.2 g
FOR MORE INFORMATION: zydususa.com


DESONIDE CREAM, 0.05%
MARKETED BY:
Glenmark Pharmaceuticals Inc, USA
COMPARE TO: Desonide Cream, 0.05% (Perrigo Company plc)
INDICATION: The FDA has approved Glenmark Pharmaceuticals’ generic version of Desonide Cream, 0.05%, to treat inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses.
DOSAGE FORM: Topical
FOR MORE INFORMATION: glenmarkpharma.com


SEVELAMER CARBONATE TABLETS, 800 MG
MARKETED BY:
Aurobindo Pharma USA
COMPARE TO: Renvela (Genzyme Corporation)
INDICATION: The FDA has approved Aurobindo’s Sevelamer Carbonate Tablets, 800 mg, the generic version of Renvela, indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
DOSAGE FORM: Tablet, 800 milligrams
FOR MORE INFORMATION: aurobindo.com


ESTRADIOL VAGINAL INSERTS
MARKETED BY:
Teva Pharmaceutical Industries Ltd
COMPARE TO: Vagifem (Novo Nordisk, Inc)
INDICATION: Teva has launched its generic version of Vagifem (estradiol vaginal inserts), 10 mcg, in the United States. Estradiol vaginal inserts are an estrogen indicated for the treatment of atrophic vaginitis due to menopause.
DOSAGE FORM: Vaginal insert, 10 mcg
FOR MORE INFORMATION: tevapharm.com

SHARE THIS SHARE THIS
0
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.